Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma: Assessment of Tolerability and In Vivo Expansion γδ T-Cells
Pilot Study of Zoledronic Acid and Interleukin-2 for Refractory Pediatric Neuroblastoma: Assessment of Tolerability and In Vivo Expansion γδ T-Cells
Neuroblastoma (NB) is the most common extracranial solid tumor in children, with an annual incidence of 10.5 per million children less than 15 years of age. NB accounts for 15% of childhood cancer deaths. High risk (HR) patients carry a poor prognosis despite treatment with intensive chemotherapy, surgery and/or radiation, autologous bone marrow transplant, and treatment with cis-retinoic acid. New therapies are desperately needed for such patients. Recently, it has been demonstrated that HR NB patients benefit from anti-GD2 antibody therapy which directs the immune system against NB cells. To further explore means of harnessing the immune system to attack NB, the investigators are studying the combination of zoledronic acid (ZOL) and interleukin-2 (IL-2). ZOL has been demonstrated to have direct anti-neuroblastoma effects in laboratory studies. ZOL also augments the production of tumor killing white blood cells called gamma-delta T cells. When used in combination with IL-2, ZOL is capable of eliciting potent anti-cancer effects in patients, in part, via the expansion of gamma-delta T cells. In this present trial the investigators aim to study the tolerability of the combination of ZOL and IL-2 in pediatric NB patients. Patients will also be monitored radiologically for tumor response to therapy. Correlative biological studies will study the ability of this drug combination to elicit the production of NB killing gamma-delta T cells in children.
Inclusion Criteria:
All patients must be diagnosed with treatment-refractory neuroblastoma with no known curative treatment options. Tumor histology should be verified at diagnosis or relapse.
Prior to enrollment, a determination of residual disease must be performed
Patients must have a Lansky or Karnofsky performance scale score of ≥ 50%.
Patients must have a life expectancy of ≥ 2 months (8 weeks).
Total absolute neutrophil count (ANC) is at least 750, Hgb≥8 grams/dl, and plts ≥ 75K. PRBC transfusions are allowed.
Patients with bone marrow disease will not evaluable for hematologic toxicity. These patients must have a peripheral absolute neutrophil count
Creatinine clearance or radioisotope GFR > 70mL/min/1.73 m2 or a serum creatinine based on age/gender as follows:
≤ 0.8 mg/dL (for patients 2 to 5 years of age)
≤ 1.0 mg/dL (for patients 6 to 9 years of age)
≤ 1.2 mg/dL (for patients 10 to 12 years of age)
≤ 1.4 mg/dL (for female patients ≥ 13 years of age)
≤ 1.5 mg/dL (for male patients 13 to 15 years of age)
≤ 1.6 mg/dL (for male patients ≥ 16 years of age)
Total bilirubin ≤ 2.5 x upper limit of normal (ULN) for age, and
SGPT (ALT) < 2.5 x upper limit of normal (ULN) for age.
SOS (sinusoidal obstruction syndrome, formerly known as veno-occlusive disease [VOD]), if present, should be stable or improving.
Shortening fraction of > 27% by echocardiogram, or ejection fraction of > 55% by radionuclide angiography.
No evidence of dyspnea at rest. If PFTs are performed, FEV1/FVC > 60% by pulmonary function test.
Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled.
CNS toxicity < Grade 2.
Exclusion Criteria: